Please use this identifier to cite or link to this item:
|Title:||Antibody-targeted drugs for the therapy of cancer.|
|Authors:||Pietersz, Geoffrey A;Krauer, K G|
|Affiliation:||Austin Research Institute, Austin Hospital, Heidelberg Vic, Australia.|
|Citation:||Journal of Drug Targeting; 2(3): 183-215|
|Abstract:||The advent of monoclonal antibodies has revitalised the concept of magic bullets and various agents (eg. drugs, toxins and isotopes) have been conjugated to monoclonal antibodies for selective delivery to tumours. Preclinical studies in mouse tumour models have been impressive and have lead to several clinical trials. These phase I trials have been less impressive. However, keeping in mind the aim of Phase I trials, the safety of using these conjugates in humans have been established. Several, major problems still remain to be overcome before these agents may be useful for the treatment of cancer. These problems stem from the nature of tumour vasculature, cytotoxic activity of the moiety linked to antibody and the targeted tumour antigen expressed on the cell surface. This review will deal with these various aspects described above and possible approaches to overcome these obstacles with a definite bias towards drug-monoclonal antibody conjugates. However, these concepts are equally applicable for improved targeting of other agents.|
|Internal ID Number:||7812691|
Antibodies, Monoclonal.immunology.metabolism.therapeutic use
Antineoplastic Agents.metabolism.therapeutic use
Disease Models, Animal
Gene Expression Regulation, Neoplastic
Immunoconjugates.adverse effects.genetics.therapeutic use.toxicity
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.